Job 60 - Assort Design

Request JD-000060 Medical Affairs

Audience: Medical Affairs • completed

Routing confidence: 90% • Candidates: Medical Affairs, R&D, Commercial

Routing reasons: ML fallback: low confidence (40% < 57%); The document discusses detailed immunological mechanisms such as class switching of antibodies, mucosal immunity and specific immune cell behaviors.; It references multi-omics immune profiling methodologies and interprets nuanced study data, which is typical for a medically informed professional audience.; Focus on vaccine efficacy, immune response modulation, and clinical implications aligns with interests of medical affairs teams focused on scientific communication and clinical data interpretation.; The article does not contain direct commercial sales pitches nor deep experimental lab research details, reducing likelihood of commercial or R&D primary audience.

Why Routed Here

Medical Affairs at 52.9% ▼

ML predicted Medical Affairs at 52.9% confidence. Runner-up: R And D at 29.7%.

Top contributing terms (Medical Affairs)

Term	TF-IDF	Weight	Contribution
`his`	0.0588	0.0719	0.0042
`hugo`	0.0812	0.0506	0.0041
`de souza`	0.0748	0.0466	0.0035
`francisco`	0.0748	0.0466	0.0035
`francisco de`	0.0748	0.0466	0.0035
`gap`	0.0562	0.0626	0.0035
`participants`	0.05	0.0709	0.0035
`souza`	0.0748	0.0466	0.0035

Runner-up: R And D (29.7%)

Term	TF-IDF	Weight	Contribution
`antibodies`	0.0782	0.0471	0.0037
`more effective`	0.0221	0.1303	0.0029
`findings`	0.0292	0.0968	0.0028
`vaccines`	0.0615	0.0462	0.0028
`and`	0.0324	0.0805	0.0026
`gene`	0.023	0.1086	0.0025
`point`	0.0263	0.0856	0.0022
`antibody`	0.0782	0.0271	0.0021

All probabilities: Commercial: 17.3% · Medical Affairs: 52.9% · R And D: 29.7%

Source url

https://www.news-medical.net/news/20260215/Nasal-COVID-vaccine-boost-increases-IgA-responses-linked-to-variant-neutralisation.aspx

Show full document

Nasal COVID vaccine boost increases IgA responses linked to variant neutralisation Skip to content Menu Medical Home Life Sciences Home Become a Member Search Medical Home Life Sciences Home About Functional Food News Health A-Z Drugs Medical Devices Interviews White Papers More... MediKnowledge eBooks Posters Podcasts Newsletters Health & Personal Care Contact Meet the Team Advertise Search Become a Member Top Health Categories Coronavirus Disease COVID-19 Diet & Nutrition Artificial Intelligence Allergies Alzheimer's & Dementia Arthritis & Rheumatology Breast Cancer Breastfeeding Cold, Flu & Cough Dermatology Diabetes Eating Disorders Eye Health Gastrointestinal Health Heart Disease Lung Cancer Mental Health Parkinson's Disease Pregnancy Sleep Urology View Health A-Z × Top Health Categories Coronavirus Disease COVID-19 Eating Disorders Diet & Nutrition Eye Health Artificial Intelligence Gastrointestinal Health Allergies Heart Disease Alzheimer's & Dementia Lung Cancer Arthritis & Rheumatology Mental Health Breast Cancer Parkinson's Disease Breastfeeding Pregnancy Cold, Flu & Cough Sleep Dermatology Urology Diabetes View Health A-Z Medical Home Life Sciences Home About News Life Sciences A-Z White Papers Lab Equipment Interviews Newsletters Webinars More... eBooks Posters Podcasts Contact Meet the Team Advertise Search Become a Member White Papers MediKnowledge eBooks Posters Podcasts Newsletters Health & Personal Care Contact Meet the Team Advertise Search Become a Member Webinars eBooks Posters Podcasts Contact Meet the Team Advertise Search Become a Member Nasal COVID vaccine boost increases IgA responses linked to variant neutralisation Download PDF Copy By Hugo Francisco de Souza Reviewed by Susha Cheriyedath, M.Sc. Feb 15 2026 A novel nasal booster approach may help close the gap between systemic vaccination and infection-blocking mucosal immunity, offering fresh insight into next-generation COVID vaccine strategies. Study: Intranasal booster drives class switching and homing of memory B cells for mucosal IgA response . Image Credit: TopMicrobialStock / Shutterstock Current intramuscular vaccines excel at eliciting blood-based immunity but sometimes fail to prevent SARS-CoV-2 transmission, a discrepancy attributed to their inability to induce a response in the upper respiratory mucosa. However, the present study evaluated immune responses rather than clinical transmission outcomes. In a recent study published in the journal JCI Insight , researchers investigated whether intranasal ( IN ) boosters could augment the efficacy of prior intramuscular COVID vaccines (inactivated whole-virus) in a small human cohort, with paired antibody analyses in six volunteers, cytokine analyses in eight volunteers, and detailed monoclonal antibody and multi-omics analyses largely derived from a single donor. Study findings demonstrated that two-dose INs (Ad5-S-Omicron vaccine) "reprogrammed" existing immune memory from previous injections, triggering a specialized "class switch" to Secretory IgA ( sIgA ) antibodies. Encouragingly, these novel nasal antibodies were observed to be substantially, in some cases hundreds-fold, more effective at neutralizing Omicron variants than standard blood antibodies. By identifying molecular features consistent with mucosal homing rather than directly tracking cell migration, this study provides preliminary mechanistic insight relevant to next-generation mucosal vaccines. Mucosal Immunity Gap and Secretory IgA Biology Since the beginning of the COVID-19 pandemic, one of the primary goals of early vaccination programs has been to reduce severe disease and hospitalization, particularly during periods of strained healthcare capacity. Early COVID vaccines were administered via intramuscular ( IM ) injection. They were intended to prevent hospitalizations by reducing the risk of severe lower respiratory tract disease, rather than by directly targeting lung tissue. Subsequent studies, however, found that these vaccines demonstrated more limited mucosal protection in the nasal and throat cavities, which are the primary entry points for SARS-CoV-2. This "entry-point gap" helped explain why even fully vaccinated individuals frequently experience breakthrough infections. Related Stories Gut microbial butyrate enhances mucosal vaccine antibody responses Single-dose HIV vaccine candidate induces neutralizing antibodies Nanovaccine design boosts immune attack on HPV tumors Recent research has identified secretory IgA (sIgA) as a potential breakthrough in nose and throat protection against COVID-19. In contrast to blood-derived single-unit antibodies, sIgA is a dimeric (two-part) structure specifically designed to survive and function on mucosal surfaces where it acts as a molecular "gatekeeper," trapping and neutralizing pathogens before they can attach to epithelial cells. Unfortunately, the human cellular mechanisms that recruit anti-SARS-CoV-2 antibodies into the nasal cavity remain incompletely understood. Study Design and Multi-Omics Immune Profiling The present study aimed to address this knowledge gap by investigating whether nasal booster vaccinations could augment the efficacy of intramuscular vaccinations in protecting individuals against future infections, and the mechanisms underpinning the recruitment of sIgA into the nasal cavity, while recognising that clinical protection outcomes were not directly measured. The study sample comprised multiple small subgroups: six participants for paired antibody potency analyses, eight for cytokine profiling, and intensive monoclonal antibody discovery largely from a single donor, which limits generalizability. Study participants received a two-dose intranasal booster with the Ad5-S-Omicron vaccine, an adenovirus-based platform encoding the spike protein of the Omicron BA.1 variant. The study leveraged next-generation "multi-omics" methodologies to monitor participants’ immune responses. These included: Mass Spectrometry of Immunoglobulin sequencing (MS Ig-seq), a liquid chromatography-tandem mass spectrometry-based approach used to identify specific antibody proteins in nasal washes. Single-cell B Cell Receptor sequencing (scBCR-seq) is a high-throughput method that enables genetic characterization of B cells responsible for the antibodies identified in MS Ig-seq. Single-cell RNA sequencing (scRNA-seq), high-throughput gene expression profiles of B cells at multiple time points (Day 10 and Day 30) to observe how and when they migrate to the nasal cavity, inferred primarily from receptor expression patterns rather than direct in vivo tracking. Using cytokine assays, the study measured the concentrations of 15 signaling proteins in nasal swabs to characterize the chemical environment that recruits immune cells to the respiratory lining. Enhanced sIgA Potency and Immune Reprogramming Study findings revealed a significant disparity between nasal and blood immunity. Purified nasal sIgA was observed to be significantly (many fold) more potent than the serum IgG found in the same individuals. Specifically, nasal sIgA was 17-fold more potent against the Wild-Type virus, 30-fold against BA.1, 125-fold against BA.5, and 813-fold against the XBB.1.5 variant. The analyses of multi-omics data successfully tracked the "reprogramming" of participants’ immune systems. Key findings included: Memory restimulation: The intranasal booster was observed to not only stimulate the creation of new immune cells, but it also restimulated "memory" B cells created by the original needle injections to secrete antibodies. Antibody class switch: Notably, these restimulated B cells underwent Class Switch Recombination ( CSR ), shifting from IgG to IgA production. The probability of this switch increased to approximately 70.8% in clonotype-level analyses, rather than the cohort-wide estimate, after the nasal booster. Gene upregulation: Following nasal booster administration, B-cell homing receptors, specifically CCR10 (Chemokine Receptor 10) and α4β1 (Integrin alpha-4 beta-1), were found to be significantly upregulated. Cytokine upregulation: The study observed a transient rise in cytokines like CCL27 and CCL28 (p < 0.05 or p < 0.01), which served as the target for the homing receptors on the surface of the IgA-secreting cells, thereby signaling these B cells to congregate in the nose, although the causal migration pathway remains incompletely defined. Clinical Implications and Durability Considerations The present study provides preliminary human evidence, albeit from small and partly single-donor analyses, that a "prime-boost" strategy, augmenting a previous intramuscular vaccine with a nasally administered adenovirus-based platform, allows for a multi-system defense from entry point (sIgA-based mucosal protection) to the lungs (IgG-based blood protection), but clinical effectiveness and durability require confirmation in larger trials. The study observed a decline in nasal sIgA levels over time (a 65% reduction within 3 months), suggesting that regular mucosal boosters may be necessary to maintain immunity. However, the implications for real-world protection remain uncertain. Journal reference: Chen, S., et al. (2026). Intranasal booster drives class switching and homing of memory B cells for mucosal IgA response. JCI Insight , 11(3):e198045. DOI, 10.1172/jci.insight.198045, https://insight.jci.org/articles/view/198045 Posted in: Medical Science News | Medical Research News | Medical Condition News | Pharmaceutical News Comments (0) Written by Hugo Francisco de Souza Hugo Francisco de Souza is a scientific writer based in Bangalore, Karnataka, India. His academic passions lie in biogeography, evolutionary biology, and herpetology. He is currently pursuing his Ph.D. from the Centre for Ecological Sciences, Indian Institute of Science, where he studies the origins, dispersal, and speciation of wetland-associated snakes. Hugo has received, amongst others, the DST-INSPIRE fellowship for his doctoral research and the Gold Medal from Pondicherry University for academic excellence during his Masters. His research has been published in high-impact peer-reviewed journals, including PLOS Neglected Tropical Diseases and Systematic Biology. When not working or writing, Hugo can be found consuming copious amounts of anime and manga, composing and making music with his bass guitar, shredding trails on his MTB, playing video games (he prefers the term ‘gaming’), or tinkering with all things tech. Download PDF Copy Citations Please use one of the following formats to cite this article in your essay, paper or report: APA Francisco de Souza, Hugo. (2026, February 15). Nasal COVID vaccine boost increases IgA responses linked to variant neutralisation. News-Medical. Retrieved on February 17, 2026 from https://www.news-medical.net/news/20260215/Nasal-COVID-vaccine-boost-increases-IgA-responses-linked-to-variant-neutralisation.aspx. MLA Francisco de Souza, Hugo. "Nasal COVID vaccine boost increases IgA responses linked to variant neutralisation". News-Medical . 17 February 2026. <https://www.news-medical.net/news/20260215/Nasal-COVID-vaccine-boost-increases-IgA-responses-linked-to-variant-neutralisation.aspx>. Chicago Francisco de Souza, Hugo. "Nasal COVID vaccine boost increases IgA responses linked to variant neutralisation". News-Medical. https://www.news-medical.net/news/20260215/Nasal-COVID-vaccine-boost-increases-IgA-responses-linked-to-variant-neutralisation.aspx. (accessed February 17, 2026). Harvard Francisco de Souza, Hugo. 2026. Nasal COVID vaccine boost increases IgA responses linked to variant neutralisation . News-Medical, viewed 17 February 2026, https://www.news-medical.net/news/20260215/Nasal-COVID-vaccine-boost-increases-IgA-responses-linked-to-variant-neutralisation.aspx. Suggested Reading Binghamton University receives $2.5 million to develop a next-generation avian flu vaccine Nasal spray vaccine prevents infection from highly pathogenic H5N1 virus Aptar Pharma’s intranasal solutions power CastleVax Phase II clinical trials for next-gen COVID-19 vaccine Study suggests shingles vaccine may help lower Alzheimer’s and dementia risk Griffith researchers on the cusp of new vaccine to prevent chikungunya COVID vaccination not linked to reduced childbirth New DNA-based vaccine scaffolds boost targeted immune responses to HIV Novel antibody 007 targets the elusive HIV envelope epitope Comments The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical. Cancel reply to comment Post a new comment Login (Logout) Quirky Comment Title Post Trending Stories Latest Interviews Top Health Articles Case report examines potential cancer risks after mRNA vaccination Study uncovers immune trigger behind vaccine-induced immune thrombocytopenia and thrombosis Researchers identify a previously unknown cellular barrier in the brain Nasal COVID vaccine boost increases IgA responses linked to variant neutralisation Study suggests shingles vaccine may help lower Alzheimer’s and dementia risk Advancing brain microphysiological systems (bMPS) Dr. Lena Smirnova Brain microphysiological systems are reshaping in vitro neurotoxicity testing through functional validation and advanced disease modeling. PhD researcher at LifeArc Natasha Bury Targeted protein degradation presents a promising strategy to address antimicrobial resistance, focusing on innovative approaches for gram-negative bacteria. Unveiling Hidden Potential: Organoids for Disease Modeling in Neuroscience Research Rosanna Zhang In our latest interview, News-Medical speaks with Rosanna Zhang from ACROBiosystems about utilizing organoids for disease modeling in the field of neuroscience research. Astaxanthin and Human Health: Evidence on Skin, Vision, Brain, and Aging The Gut–Brain–Skin Axis: How Diet and Gut Health Influence Mood, Skin, and Aging How Morning Routines Influence Cognitive Performance, Mood, and Circadian Rhythm Camel Milk Nutrition Facts and Potential Health Benefits Explained Edible Insects as Food: Nutritional Benefits, Safety, and Environmental Impact Latest News JAX-NYSCF collaborates with GSK to advance human cellular models of neurodegenerative disease Musicians experience higher rates of tinnitus, hearing loss, and hyperacusis than non-musicians M-PACT sets new standard for pediatric brain tumor diagnostics, treatment monitoring Insilico Medicine and MSK collaborate to discover new drug targets for gastroesophageal malignancies Mayo Clinic collaborates with New Phase Ltd. to install magnetic nanoparticle hyperthermia machine for cancer research Newsletters you may be interested in COVID-19 ( Subscribe or Preview ) Genetics ( Subscribe or Preview ) Alzheimer's Disease ( Subscribe or Preview ) See all Newsletters » High Credibility: This website adheres to all nine standards of credibility and transparency. Medical Links Medical Home Functional Food News Health A-Z White Papers Thought Leaders Insights MediKnowledge Series Health & Personal Care Medical Devices Drugs eBooks Posters Podcasts Life Sciences Links Life Sciences Home News Lab Instruments & Equipment Life Sciences A-Z White Papers Thought Leaders Insights Webinars eBooks Posters Podcasts Other Useful Links About Meet the Team Search Newsletters Sitemap Advertise Contact Terms & Conditions Privacy & Cookie Policy Content Policy Ownership & Funding Information Other AZoNetwork Sites AZoM AZoNano AZoCleantech AZoOptics AZoRobotics AZoSensors AZoMining AZoQuantum AZoBuild AZoLifeSciences AZoAi Facebook Twitter LinkedIn News-Medical.Net provides this medical information service in accordance with these terms and conditions . Please note that medical information found on this website is designed to support, not to replace the relationship between patient and physician/doctor and the medical advice they may provide. Update Your Privacy Preferences Last Updated: Tuesday 17 Feb 2026 News-Medical.net - An AZoNetwork Site Owned and operated by AZoNetwork, © 2000-2026 Azthena logo with the word Azthena Maximise chat window Hide chat window Your AI Powered Scientific Assistant Hi, I'm Azthena, you can trust me to find commercial scientific answers from News-Medical.net. To start a conversation, please log into your AZoProfile account first, or create a new account. Registered members can chat with Azthena, request quotations, download pdf's, brochures and subscribe to our related newsletter content . Log in A few things you need to know before we start. Please read and accept to continue. Use of “Azthena” is subject to the terms and conditions of use as set out by OpenAI . Content provided on any AZoNetwork sites are subject to the site Terms & Conditions and Privacy Policy . Large Language Models can make mistakes. Consider checking important information. I understand, and agree to receive occasional emails about Azthena such as usage tips and new feature announcements. Please check the box above to proceed. Start Chat Great. Ask your question. Clear Chat Clear Chat Brief Moderate Detailed Azthena may occasionally provide inaccurate responses. Read the full terms . Terms While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided. Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles. Please do not ask questions that use sensitive or confidential information. Read the full Terms & Conditions . Provide Feedback Submit Cancel You might also like... × Immunocompromised individuals require multiple Covid booster doses

An intranasal COVID-19 vaccine booster significantly enhances mucosal secretory IgA responses, improving neutralization of variants and complementing systemic immunity.

5 bullets 4 citations (0 strong) 7 tags 6 clues 1 high-risk flag

📊

View Analysis

Full breakdown — bullets, mind map, citations, risk & scorecard

📄

View Source

Original URL and scraped document text

One-line Summary

An intranasal COVID-19 vaccine booster significantly enhances mucosal secretory IgA responses, improving neutralization of variants and complementing systemic immunity.

Decision Bullets

Scientific Summary: Intranasal Ad5-S-Omicron vaccine booster reprograms memory B cells to secrete secretory IgA, enhancing mucosal neutralization of SARS-CoV-2 variants including Omicron sublineages.

View citation support (1)

Study: Intranasal booster drives class switching and homing of memory B cells for mucosal IgA response .

…ccination and infection-blocking mucosal immunity, offering fresh insight into next-generation COVID vaccine strategies. Study: Intranasal booster drives class switching and homing of memory B cells for mucosal IgA response . Image Credit: TopMicrobialStock / Shutterstock Current intramuscular vaccines excel at eliciting blood-based immunity…

Offsets: 1957–2061

Confidence: 71% Medium
Evidence Gaps: Clinical efficacy in preventing infection or transmission remains unproven; durability and optimal booster frequency require further study in larger, diverse cohorts.

View citation support (1)

Clinical Implications and Durability Considerations The present study provides preliminary human evidence, albeit from small and partly single-donor analyses, that a "prime-boost" strategy, augmenting a previous intramuscular vaccine with a nasally administered adenovirus-based platform, allows for a multi-system defen

…y signaling these B cells to congregate in the nose, although the causal migration pathway remains incompletely defined. Clinical Implications and Durability Considerations The present study provides preliminary human evidence, albeit from small and partly single-donor analyses, that a "prime-boost" strategy, augmenting a previous intramuscular vaccine with a nasally administered adenovirus-based platform, allows for a multi-system defe nse from entry point (sIgA-based mucosal protection) to the lungs (IgG-based blood protection), but clinical effectivene…

Offsets: 8439–8759

Confidence: 76% Medium
Medical Insights: Mucosal immunity via sIgA is a critical complement to systemic immunity and may reduce viral entry; nasal delivery can enhance mucosal homing and antibody class switching.

View citation support (1)

Feb 15 2026 A novel nasal booster approach may help close the gap between systemic vaccination and infection-blocking mucosal immunity, offering fresh insight into next-generation COVID vaccine strategies.

…onses linked to variant neutralisation Download PDF Copy By Hugo Francisco de Souza Reviewed by Susha Cheriyedath, M.Sc. Feb 15 2026 A novel nasal booster approach may help close the gap between systemic vaccination and infection-blocking mucosal immunity, offering fresh insight into next-generation COVID vaccine strategies . Study: Intranasal booster drives class switching and homing of memory B cells for mucosal IgA response . Image Credit:…

Offsets: 1751–1956

Confidence: 68% Medium
Stakeholder Considerations: Vaccine developers should pursue intranasal platforms to address mucosal immunity gaps; regulators need clinical trial data on transmission prevention; public health messaging must manage expectations about durability.

View citation support (1)

No supporting quote found.

Confidence: 20% Weak
Next Steps: Conduct larger controlled clinical trials assessing protection against infection and transmission; investigate mechanisms of B cell migration; assess long-term durability and optimal booster timing.

View citation support (1)

Study Design and Multi-Omics Immune Profiling The present study aimed to address this knowledge gap by investigating whether nasal booster vaccinations could augment the efficacy of intramuscular vaccinations in protecting individuals against future infections, and the mechanisms underpinning the recruitment of sIgA in

… human cellular mechanisms that recruit anti-SARS-CoV-2 antibodies into the nasal cavity remain incompletely understood. Study Design and Multi-Omics Immune Profiling The present study aimed to address this knowledge gap by investigating whether nasal booster vaccinations could augment the efficacy of intramuscular vaccinations in protecting individuals against future infections, and the mechanisms underpinning the recruitment of sIgA i nto the nasal cavity, while recognising that clinical protection outcomes were not directly measured. The study sample c…

Offsets: 5013–5333

Confidence: 67% Medium

Mind Map

mindmap
  root((Intranasal COVID-19 Booster))
    Scientific_Summary
      class_switching(IgG to IgA)
      enhanced_neutralization(Mucosal sIgA potency)
    Evidence_Gaps
      clinical_efficacy(Unknown protection against transmission)
      durability(Waning sIgA levels)
      sample_size(Limited cohort)
    Medical_Insights
      mucosal_immunity(sIgA importance)
      immune_reprogramming(Memory B cell restimulation)
    Stakeholder_Considerations
      vaccine_development(Intranasal platforms)
      regulatory_needs(Clinical data on transmission)
      public_health_message(Durability and booster frequency)
    Next_Steps
      larger_trials(Clinical efficacy and safety)
      migration_mechanisms(B cell homing pathways)
      durability_studies(Long-term immunity)

#	Bullet	Supporting Quote	Level
1	Scientific Summary: Intranasal Ad5-S-Omicron vaccine booster reprograms memory B cells to secrete secretory IgA, enhancing mucosal neutralization of SARS-CoV-2 variants including Omicron sublineages.	"Study: Intranasal booster drives class switching and homing of memory B cells for mucosal IgA response ."	Medium
2	Evidence Gaps: Clinical efficacy in preventing infection or transmission remains unproven; durability and optimal booster frequency require further study in larger, diverse cohorts.	"Clinical Implications and Durability Considerations The present study provides preliminary human evidence, albeit from small and partly single-donor analyses, that a "prime-boost" strategy, augmenting a previous intramuscular vaccine with a nasally administered adenovirus-based platform, allows for a multi-system defen"	Medium
3	Medical Insights: Mucosal immunity via sIgA is a critical complement to systemic immunity and may reduce viral entry; nasal delivery can enhance mucosal homing and antibody class switching.	"Feb 15 2026 A novel nasal booster approach may help close the gap between systemic vaccination and infection-blocking mucosal immunity, offering fresh insight into next-generation COVID vaccine strategies."	Medium
4	Stakeholder Considerations: Vaccine developers should pursue intranasal platforms to address mucosal immunity gaps; regulators need clinical trial data on transmission prevention; public health messaging must manage expectations about durability.	—	None
5	Next Steps: Conduct larger controlled clinical trials assessing protection against infection and transmission; investigate mechanisms of B cell migration; assess long-term durability and optimal booster timing.	"Study Design and Multi-Omics Immune Profiling The present study aimed to address this knowledge gap by investigating whether nasal booster vaccinations could augment the efficacy of intramuscular vaccinations in protecting individuals against future infections, and the mechanisms underpinning the recruitment of sIgA in"	Medium

Attempt Timeline

Attempt 1

Attempts

Attempt 1 — Passed
An intranasal COVID-19 vaccine booster significantly enhances mucosal secretory IgA responses, improving neutralization of variants and complementing systemic immunity.

View Debug

Trace Legend